文献速递眼底病与葡萄膜炎白内障与屈光手术青光眼

眼科临床范式转变:从光学修复到基因矫正

Mastering the eye: Clinical paradigm shifts from optical restoration to genomic correction.
PubMed 文献 · Prog Retin Eye Res · 2026-10-20

综述回顾20世纪中叶以来七项重塑眼科诊疗的进展,包括人工晶状体、超声乳化、玻璃体切除、OCT、内皮角膜移植、抗VEGF治疗、微创青光眼手术和基因治疗。部分进展证据确定性高(如抗VEGF),部分低(如成像对患者结局的影响)。每项进展均带来新负担,常规应用依赖制造、监管、成本与卫生系统能力。

要点

  • 七项进展中五项开创了新型干预,内皮角膜移植和微创青光眼手术提升了现有手术安全性。
  • 抗VEGF治疗证据确定性高,而成像技术对患者结局影响的证据确定性低。
  • 每项进展均带来新负担(如慢性注射、供体组织依赖),推广受制造与卫生系统能力制约。

核心结论

  • 眼科七项主要进展中五项开创了新型干预,两项使现有手术更安全。
  • 各进展对患者获益的证据确定性不一,部分高(如抗VEGF治疗),部分低(如成像对患者结局的影响)。

研究设计与样本

  • 综述总结七项眼科进展的最佳获益证据及其确定性,未报告检索范围与样本量。

主要发现

  • 1949年Harold Ridley植入首枚人工晶状体,1967年Charles Kelman与Anton Banko报告超声乳化。
  • 1970年Robert Machemer实施首例经平坦部玻璃体切除,1991年David Huang等描述OCT。
  • 1998至2006年间Gerrit Melles等开发内皮角膜移植,仅替换病变角膜内皮而非全层角膜。
  • 抗VEGF治疗基于1989年VEGF纯化及2006年雷珠单抗获批,微创青光眼手术自2012年推广。
  • 2017年voretigene neparvovec成为首个获批用于遗传性视网膜疾病的基因治疗。

临床怎么用

  • 抗VEGF治疗等证据确定性高的进展可作为临床决策的可靠依据。
  • 成像技术等证据确定性低的进展需结合临床判断,不宜过度依赖其改善患者结局的假设。
  • 推广新技术需综合评估制造、监管、成本、报销和卫生系统能力。

局限性

  • 未报告检索范围、纳入标准及证据确定性评估方法。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Historically, the main operation for cataract was couching, and the interior of the living eye could not be examined until Hermann von Helmholtz introduced the ophthalmoscope in 1851. Since the mid-twentieth century, seven advances have reshaped ophthalmic care. Harold Ridley implanted the first intraocular lens in 1949, and the ophthalmologist Charles Kelman and the engineer Anton Banko developed phacoemulsification, reported in 1967. Robert Machemer performed the first pars plana vitrectomy in 1970, while David Huang and colleagues described optical coherence tomography in 1991. Endothelial keratoplasty, developed by Gerrit Melles and others between 1998 and 2006, replaced only the failing corneal endothelium instead of the full thickness of the cornea. Anti-VEGF therapy followed the purification of VEGF by Napoleone Ferrara and colleagues in 1989 and the approval of ranibizumab in 2006. Minimally invasive glaucoma surgery has spread since 2012, and in 2017 voretigene neparvovec became the first approved gene therapy for an inherited retinal disease. Five of these advances enabled a new type of intervention, whereas endothelial keratoplasty and minimally invasive glaucoma surgery made existing operations safer. For each advance we summarize the best available evidence of benefit to patients and its certainty, which is high for some, such as anti-VEGF therapy, and low for others, such as the effect of imaging on patient outcomes. Each advance created new burdens, from chronic injections to dependence on donor tissue, and routine adoption depended on manufacturing, regulation, cost, reimbursement, and health-system capacity.

来源:Prog Retin Eye Res,查看原文。版权归原作者所有。

引用

  1. Zhang X, Li F, Huang D, et al. Mastering the eye: Clinical paradigm shifts from optical restoration to genomic correction. Prog Retin Eye Res. 2026. PMID: 42901316. doi:10.1016/j.preteyeres.2026.101537

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。